Xenon Pharmaceuticals Inc. (XENE) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Burnaby, BC, Canada. Der aktuelle CEO ist Ian C. Mortimer.
XENE hat IPO-Datum 2014-11-05, 316 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $4.69B.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Burnaby, Canada, focused on developing innovative therapeutics for neurological disorders. The company's pipeline includes XEN496 and XEN1101, both Kv7 potassium channel openers in clinical development for epilepsy and related conditions, as well as NBI-921352, a sodium channel inhibitor in Phase II trials for developmental and epileptic encephalopathy. Additionally, Xenon is advancing XEN007, a central nervous system calcium channel modulator, and has partnered with Neurocrine Biosciences for epilepsy treatments and Flexion Therapeutics for pain management applications. Founded in 1996, the company is committed to addressing significant unmet medical needs in neurological disorders through its targeted drug development approach.
